Trials
No article body is available. No grounded facts about AstraZeneca's obesity program or the $125M deal can be confirmed from this source.
AstraZeneca tested a pill form of GLP-1 (a weight-loss and diabetes drug) in mid-stage trials and saw promising results. The company doesn't yet know how well it works compared to other pill versions on the market.
AstraZeneca's oral GLP-1 pill showed promise in mid-stage trials. It adds a new rival in the race to make a weight-loss pill, but head-to-head data vs other pills isn't available yet.
Eli Lilly's pill version of orforglipron (Foundayo) beat Novo Nordisk's semaglutide pill at lowering blood sugar and weight loss in three large diabetes trials. Foundayo showed bigger drops in A1C levels and weight compared to the competing drug.
Lilly's orforglipron pill beat Novo's semaglutide pill on blood sugar and weight in three trials. That puts Lilly in a strong spot in the oral diabetes drug race.
Eli Lilly released new safety and side-effect data on retatrutide, its next-generation weight-loss drug. The data give doctors more details about how the drug works in patients.
New safety data on Lilly's retatrutide gives doctors a clearer picture of the drug before it reaches later-stage trials.
Boehringer Ingelheim released Phase 3 trial results for survodutide, its obesity drug. The drug cut liver fat well but didn't reduce weight as much as some competitors, raising questions about how it will compete in the market.
Survodutide's Phase 3 weight loss looks weaker than rivals. That may make it harder to sell against Ozempic and Zepbound when it reaches market.
Eli Lilly's Foundayo (orforglipron), an oral weight-loss drug you can take with food or water, helped women lose significant weight in two trials. Women in perimenopause lost up to 30.4 pounds, and those past menopause lost up to 28.2 pounds.
Orforglipron showed weight loss in women at all menopause stages. This expands the pool of patients Lilly can target with its oral GLP-1 pill.
Eli Lilly shared safety and tolerability data on retatrutide, its next-generation weight-loss drug, at the American Diabetes Association's annual meeting. The data shows how well the drug works and what side effects patients experienced during testing.
Lilly's retatrutide safety data at a major medical meeting helps show if the drug is safe enough to move forward. Good results push it closer to market.
Eli Lilly's retatrutide, a triple-action weight-loss drug, helped people lose an average of 70 pounds over 80 weeks in a major trial. The drug also reduced joint pain and improved sleep problems in people with obesity and related conditions.
Retatrutide cut weight, joint pain, and sleep problems in one trial. That makes Lilly's drug look stronger than current options for people with obesity plus other conditions.
Pfizer showed new details from a midstage trial of its obesity drug berobenatide, which the company bought from Metsera. The drug appears to work when given once a month instead of more often.
Pfizer's once-a-month obesity drug shows promise in mid-stage testing. A monthly shot could be easier for patients than weekly options.
Eli Lilly will present new study results on Foundayo (an oral weight-loss and diabetes drug), Mounjaro, and retatrutide at a major diabetes conference. The Foundayo data showed it worked better than two competing pills for type 2 diabetes.
Lilly is showing new data on three drugs at once. Foundayo beating rival pills for type 2 diabetes could help doctors choose it over competitors.
Eli Lilly's new weight-loss pill Foundayo helped older adults lose up to 13% of their body weight in a large trial. The drug is taken once daily without needing to avoid food or water first.
Foundayo showed up to 13% weight loss in adults 65+ with obesity. This age group is a large, underserved market for Lilly's oral pill.
Eli Lilly's retatrutide, a weight-loss drug that works three different ways in the body, helped people in a major trial lose about one-quarter of their body weight. This result may be stronger than what competitors like Novo Nordisk have shown with their own weight-loss drugs.
Retatrutide hit its Phase 3 goal with around 25% body weight loss. That may top Novo Nordisk's drugs and puts Lilly in a strong spot in the obesity market.
Eli Lilly said its new obesity drug worked almost as well as weight-loss surgery in a late-stage trial. The company tested the drug on people struggling with weight to see if it could help them lose pounds.
Lilly says a new obesity drug matched surgery results in a late trial. No trial details or drug name were confirmed in the source.
Eli Lilly's retatrutide, a new weight-loss drug that works three different ways, helped people lose an average of 70 pounds in a big Phase 3 trial. Nearly half of patients lost at least 30% of their body weight, which is as much as people usually lose from weight-loss surgery.
Retatrutide's Phase 3 results show weight loss close to surgery levels. This puts Lilly ahead in the obesity drug race and pressures rivals like Novo Nordisk.
Eli Lilly's retatrutide (a three-hormone weight-loss drug) helped patients lose as much weight as bariatric surgery in a trial. However, some patients quit the study because of side effects.
Lilly's retatrutide matched bariatric surgery weight loss in a trial. That is a big deal for people who can't or won't have surgery.
Eli Lilly's trial data suggests that people losing weight on high-dose shot versions of its drug could switch to lower doses or pills and still keep the weight off. The findings point to cheaper, easier ways to maintain weight loss once someone has hit their goal.
Lilly data suggest people could switch from costly high-dose shots to cheaper pills or lower doses and keep weight off. That widens how many patients can afford to stay on Lilly drugs long-term.
Eli Lilly released results from two late-stage trials showing that people who switched from higher-dose Wegovy or Zepbound to lower doses of Lilly's Foundayo pill or lower-dose Zepbound kept nearly all their weight loss over one year. The trials suggest the lower doses work well enough to maintain results when people switch from stronger versions.
Lilly's pill Foundayo may let patients step down from high-dose shots and keep their weight off. That could pull patients away from Novo's Wegovy.
Lilly is testing tirzepatide with a Regeneron drug to treat obesity. If it works, patients could get a stronger weight-loss option than Zepbound alone.
Semaglutide, a weight-loss drug, reduced heavy drinking in people with alcohol use disorder during a trial. The finding suggests the drug might help treat addiction, not just weight loss.
Semaglutide may help people drink less, not just lose weight. That could open a new use for Novo's drug if bigger trials confirm it.
Semaglutide is being studied as a possible help for people who drink too much. If it works, Novo's drug could treat far more than diabetes and weight loss.
Novo is testing two new diabetes drugs in people. New trials show the company is still building its pipeline beyond Ozempic.
Novo Nordisk stopped testing a version of CagriSema, a peptide drug being developed for weight loss and diabetes. The company did not explain why it halted the clinical trial.
Novo's next big weight-loss drug just lost a version in testing. That hurts its push to catch Lilly in the obesity drug race.
Lexaria plans to start a 5-week study of an oral form of semaglutide in mid-June. The study will test whether this pill version works as a weight-loss treatment.
A small company is testing its own pill version of semaglutide. Early-stage work like this rarely moves the market, but oral GLP-1s are a hot area.
Wegovy (a weight-loss drug) may help people drink less alcohol, according to a new trial. The finding suggests the drug could treat alcohol addiction, not just weight.
Wegovy may help people cut back on heavy drinking. If more trials confirm this, Novo could sell the drug for alcohol use disorder, not just weight loss.
Novo Nordisk is testing semaglutide (a weight-loss drug) in people with alcohol problems and running a trial of LX9851 (a new drug similar to semaglutide). Both studies show the company is exploring new uses for its peptide medicines.
Novo is looking for new ways to use semaglutide beyond weight loss. New uses could mean more sales and a stronger drug pipeline.
Amgen started three big trials for MariTide, its obesity drug. One trial will test MariTide in patients switching away from rival weight-loss drugs made by Eli Lilly and Novo Nordisk.
Amgen wants to prove MariTide works for people who quit Ozempic or Zepbound. A win could pull patients away from Lilly and Novo.
A new peptide drug is being tested to protect kidneys during heart surgery. It is early-stage work, so results are far off.
Retatrutide, an experimental weight-loss drug, showed patients lost 28.7% of their body weight in a trial. An intellectual property firm says the real competition next will be over patents as other companies try to develop similar drugs.
Lilly's retatrutide showed bigger weight loss than today's top drugs. The next fight will be over patents as rivals try to copy the formula.
Boehringer's survodutide, a GLP-1 drug that works two ways to help control weight and blood sugar, passed a major late-stage trial (Phase 3). The results show the drug works well and may move toward approval.
Survodutide hit its goal in a late-stage trial. That gives Boehringer and Zealand a real shot at the obesity market now ruled by Lilly and Novo.
Boehringer's dual agonist drug (a weight-loss medicine that works in two ways) helped people lose up to 16.6% of their body weight in testing. This is an early result from the company's obesity drug program.
Boehringer's drug joins the race against Wegovy and Zepbound. More options could mean lower prices and more supply for people who need weight-loss drugs.